Trial reportPloS one2019
The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole.
Trial report in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- System-based insights into parasitological and clinical treatment failure in Chagas disease.mSystems · 2025Review
- Parasite-microbiota interactions: a pathway to innovative interventions for Chagas disease, leishmaniasis, and ascariasis.Future microbiology · 2025Review
- Network Analysis of Pathogenesis Markers in Murine Chagas Disease Under Antimicrobial Treatment.Microorganisms · 2024Article
- The intersection of hostMicrobiology and molecular biology reviews : MMBR · 2024Review
- Small molecule mediators of host-T. cruzi-environment interactions in Chagas disease.PLoS pathogens · 2024Review
- Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease.Nature communications · 2023Article
- Chagas disease is related to structural changes of the gut microbiota in adults with chronic infection (TRIPOBIOME Study).PLoS neglected tropical diseases · 2023Article
- Microbiome Alterations Driven byMicrobiology spectrum · 2023Article
- Molecular and Clinical Aspects of Chronic Manifestations in Chagas Disease: A State-of-the-Art Review.Pathogens (Basel, Switzerland) · 2021Review
- The distribution and chemical coding of enteroendocrine cells in Trypanosoma cruzi-infected individuals with chagasic megacolon.Histochemistry and cell biology · 2021Article
- Shared neuroimmune and oxidative pathways underpinning Chagas disease and major depressive disorder.Translational psychiatry · 2020Review
- NOD2 receptor is crucial for protecting against the digestive form of Chagas disease.PLoS neglected tropical diseases · 2020Article
- Mapping of host-parasite-microbiome interactions reveals metabolic determinants of tropism and tolerance in Chagas disease.Science advances · 2020Article
- Gut Dysbiosis in Chagas Disease. A Possible Link to the Pathogenesis.Frontiers in cellular and infection microbiology · 2020Article
- Targeting the Gut Microbiota in Chagas Disease: What Do We Know so Far?Frontiers in microbiology · 2020Review
- Correction: The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole.PloS one · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChagas disease is still prevalent in rural areas of South America. In endemic areas of Bolivia, school children are screened for the program of Chagas disease eradication of the Ministry of Health, and positive children are treated. Here, we compared the fecal, oral and skin microbiomes of children with or without Chagas disease, and before and after benznidazol treatment of infected children.
methodsA total of 543 Bolivian children (5-14 years old) were tested for Chagas disease, and 20 positive children were treated with Benznidazole. Fecal samples and oral and skin swabs were obtained before and after treatment, together with samples from a group of 35 uninfected controls. The 16S rRNA genes were sequenced and analyzed using QIIME to determine Alpha diversity differences and community distances, and linear discriminant analyses to determine marker taxa by infection status or treatment.
resultsTwenty out of 543 children screened were seropositive for Chagas disease (3.7%) and were included in the study, together with 35 control children that were seronegative for the disease. Fecal samples, oral and skin swabs were taken at the beginning of the study and after the anti-protozoa therapy with Benznidazole to the chagasic children. Infected children had higher fecal Firmicutes (Streptococcus, Roseburia, Butyrivibrio, and Blautia), and lower Bacteroides and also showed some skin -but not oral- microbiota differences. Treatment eliminated the fecal microbiota differences from control children, increasing Dialister (class Clostridia) and members of the Enterobacteriaceae, and decreasing Prevotella and Coprococcus, with minor effects on the oral and skin bacterial diversity.
conclusionsThe results of this study show differences in the fecal microbiota associated with Chagas disease in children, and also evidence that treatment normalizes fecal microbiota (makes it more similar to that in controls), but is associated with oral and skin microbiota differences from control children. Since microbiota impacts in children, it is important to determine the effect of drugs on the children microbiota, since dysbiosis could lead to physiological effects which might be avoidable with microbiota restoration interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.